• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by G Medical Innovations Holdings Ltd. (Amendment)

    8/8/23 2:53:57 PM ET
    $GMVD
    Medical/Dental Instruments
    Health Care
    Get the next $GMVD alert in real time by email
    SC 13G/A 1 G_Medical_Innovations_Hold.htm FILING G MEDICAL INNOVATIONS HOLDINGS LTD. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    G Medical Innovations Holdings Ltd. 

    (Name of Issuer)
     
    Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)
     
    G39462141

    (CUSIP Number)
     
    July 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  G39462141            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      60,196
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      60,196
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      60,196
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0.6 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    G Medical Innovations Holdings Ltd.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    5 Oppenheimer St.,
    Rehovot 7670105, Israel


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Ordinary Shares, par value $0.0001 per share


     
    (e)
    CUSIP Number
     
     
    G39462141


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 60,196


     
    (b)
    Percent of class: 0.6 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 60,196


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 60,196


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. MORGAN SECURITIES AUSTRALIA LIMITED
    J.P. Morgan Securities LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: August 08, 2023
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $GMVD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GMVD

    DatePrice TargetRatingAnalyst
    1/18/2022$6.00Buy
    EF Hutton
    More analyst ratings

    $GMVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on G Medical Innovations with a new price target

      EF Hutton initiated coverage of G Medical Innovations with a rating of Buy and set a new price target of $6.00

      1/18/22 9:06:41 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Awm Investment Company, Inc.

      4 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)

      4/4/23 4:21:22 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form 3: New insider Awm Investment Company, Inc. claimed ownership of 1,437,500 shares

      3 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)

      4/4/23 4:10:17 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    SEC Filings

    See more
    • SEC Form 6-K filed by G Medical Innovations Holdings Ltd.

      6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      12/18/23 4:39:15 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by G Medical Innovations Holdings Ltd.

      6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      11/29/23 9:27:53 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form D filed by G Medical Innovations Holdings Ltd.

      D - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      10/25/23 8:42:02 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • G Medical Innovations Will Provide Services to Veterans and Military Personnel by Partnering With Resilient Support Services

      Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations"), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. ("RSS") to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community.  G Medi

      8/17/23 6:00:00 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • G Medical Innovations' CEO Issues Update to Shareholders, August 2023

      Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations" or the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva. Dear Fellow Shareholders, We are proud to report that at this halfway point of 2023, G Medical has met several significant milestones and is on track to show revenue growth and gain profitability. Our Company has experienced growth in its monitoring services, and we are getting ready to add revenue with our "At Home Test Kits" business unit as we are no

      8/7/23 9:27:00 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

      Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the "Notice") from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.

      5/19/23 4:15:00 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Financials

    Live finance-specific insights

    See more
    • G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

      Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical" or the "Company"), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022. First Half 2022 Financial Results During the six months period ended June 30, 2022, the Company performed over 100,000 tests which includes four types of diagnostic tests –Rapid Antigen, A/B Flu, PCR and Antibody; in connection with these tests, the Company expects to submit approximately

      11/18/22 5:15:00 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      2/7/24 1:12:01 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      10/24/23 3:56:02 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      8/25/23 4:15:27 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care